A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women.

Trial Profile

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol
  • Indications Pregnancy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Teva Womens Health
  • Most Recent Events

    • 06 May 2013 Data will be presented at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists (ACOG-2013), according to a Teva Women's Health media release.
    • 13 Nov 2012 Results were presented at the 68th Annual Meeting of the American Society of Reproductive Medicine (ASRM).
    • 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top